Literature DB >> 19417173

Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.

W Crasto1, J Jarvis, E Hackett, V Nayyar, P G McNally, M J Davies, I G Lawrence.   

Abstract

Some patients with type 2 diabetes mellitus (T2DM) are profoundly insulin resistant and require large insulin doses to achieve optimal glycaemic control. However, large volumes of subcutaneous conventional U-100 insulin can cause discomfort at the injection site, resulting in poor concordance with insulin therapy. One therapeutic option is the use of U-500 insulin, thus reducing the insulin volume by 80%. This review will address the practical issues associated with the use of U-500, clinical efficacy and safety aspects of this concentrated insulin, which has an important role in a subgroup of patients with T2DM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417173     DOI: 10.1136/pgmj.2008.073379

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  6 in total

1.  U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.

Authors:  Jolene Brown Lowery; Amy C Donihi; Mary T Korytkowski
Journal:  Diabetes Technol Ther       Date:  2012-02-24       Impact factor: 6.118

Review 2.  Clinical use of U-500 regular insulin: review and meta-analysis.

Authors:  Sirimon Reutrakul; Kristen Wroblewski; Rebecca L Brown
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

3.  Paradigm shift in the management of type B insulin resistance.

Authors:  Jun Hwa Hong; Hyun Jin Kim; Kang Seo Park; Bon Jeong Ku
Journal:  Ann Transl Med       Date:  2018-12

4.  Clinical efficacy and patient satisfaction with U-500 insulin use.

Authors:  Alexandria M Dailey; Sarah Williams; Deepa Taneja; Lisa R Tannock
Journal:  Diabetes Res Clin Pract       Date:  2010-03-11       Impact factor: 5.602

5.  Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.

Authors:  Stephen C L Gough; Anuj Bhargava; Rajeev Jain; Henriette Mersebach; Søren Rasmussen; Richard M Bergenstal
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112

6.  Treatment Approach to Patients With Severe Insulin Resistance.

Authors:  Timothy J Church; Stuart T Haines
Journal:  Clin Diabetes       Date:  2016-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.